VJHemOnc is committed to improving our service to you

EBMT 2019 | First-in-human bispecific CAR T-cell therapy for R/R non Hodgkin lymphoma

VJHemOnc is committed to improving our service to you

Nirav Niranjan Shah

Nirav Niranjan Shah, MD, from the Medical College of Wisconsin, Milwaukee, WI, delivers updates from the first-in-human Phase I dose-escalation study of bispecific anti-CD19, anti-CD20 CAR T-cells (CAR-20.19-T) for relapsed/refractory non-Hodgkin Lymphoma (NCT03019055). Dr Shah was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter